Abstract
The bioavailability of propranolol was compared after oral, sublingual, and intranasal administration in eight healthy male volunteers. Relative to the bioavailability after intranasal (in) administration, which was previously shown to be nearly complete (F relin = 100%), the sublingual (sl) administration of a standard 10-mg tablet gave a bioavailability of F relsl = 63 ± 22%, while the oral (or) administration yielded only F relor = 25 ± 8%. The serum concentration–time curves of propranolol after sublingual administration resembled those of a sustained-release preparation. This sustained-release phenomenon after the sublingual route is reflected in the mean residence times (MRTs) of propranolol in the body (MRTor = 5.7 ± 1.3 hr, MRTsl - 6.4 ± 1.3 hr, MRTin = 4.6 ± 1.0 hr; mean ± SD; N = 8). MRTs after sublingual administration were significantly longer than after the oral and the intranasal doses (P < 0.05 and P < 0.002, respectively).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
W. Frishman. Am. Heart J. 97:663–670 (1979).
C. G. Reg{ie111-1}rdh. Acta Med. Scand. Suppl. 665:49–60 (1982).
E. Vervloet, B. F. M. Pluym, J. Cilissen, K. Köhlen, and F. W. H. M. Merkus. Clin. Pharmacol. Ther. 22:853–857 (1977).
A. J. McLean, C. Isbister, A. Bobik, and F. J. Dudley. Clin. Pharmacol. Ther. 30:31–34 (1981).
A. Hussain, T. Foster, S. Hirai, T. Kashihara, R. Batenhorst, and M. Jones. J. Pharm. Sci. 69:1240 (1980).
D. C. Hicks. Br. J. Pharmacol. 47:680P–681P (1973).
J. A. Henry, K. Ohashi, J. Wadsworth, and P. Turner. Br. J. Clin. Pharmacol. 10:61–65 (1980).
R. E. Kates. J. Med. 8:393–402 (1977).
L. G. J. de Leede, C. G. Hug, S. de Lange, A. G. de Boer, and D. D. Breimer. Clin. Pharmacol. Ther. 35:148–155 (1984).
M. Bende, K. Flisberg, I. Larsson, P. Omlin, and P. Olson. Acta Otolaryngol. 96:277–285 (1983).
H. J. M. van de Donk and F. W. H. M. Merkus. J. Pharm. Sci. 71:595–596 (1982).
W. J. Warwick. Eur. J. Resp. Dis. 64 (Suppl. 127):162–167 (1983).
G. S. M. J. E. Duchateau, K. Graamans, J. Zuidema, and F. W. H. M. Merkus. Laryngoscope 95:854–859 (1985).
R. H. Cotham and D. Shand. Clin. Pharmacol. Ther. 18:535–538 (1975).
S. Riegelman and P. Collier. J. Pharmacokin. Biopharm. 8:509–535 (1980).
R. Doornbos and H. J. Prins. Indag. Math. 20:38–55, 438–447 (1958).
D. Dvornik, M. Kraml, J. Dubuc, J. Coelho, L. A. Novello, J. D. Arnold, and J. F. Mullane. Curr. Ther. Res. 34:595–605 (1983).
E. Perucca, R. Grimaldi, G. Gatti, M. Caravaggi, F. Crema, S. Lecchini, and G. M. Frigo. Br. J. Clin. Pharmacol. 18:37–43 (1984).
K. Ohashi, A. Ebihara, K. Kondo, and M. Usami. Arzneim.-Forsch./Drug Res. 34 (I):507–512 (1984).
A. H. Beckett, R. N. Boyes, and E. J. Triggs. J. Pharm. Pharmacol. 20:92–97 (1968).
W. Schürmann and P. Turner. J. Pharm. Pharmacol. 30:137–147 (1978).
L. G. Patel, S. J. Warrington, and R. M. Pearson. Br. Med. J. 287:1247–1248 (1983).
R. M. Pearson, E. J. Ridgway, A. Johnston, and J. Vadukul. Lancet II:1480 (1984).
H. P. Blumenthal, Ho-Leung Fung, E. F. McNiff, and S. K. Yap. Br. J. Clin. Pharmacol. 4:241–242 (1977).
H. Maier-Lenz, L. Ringwelski, and A. Windorfer. Arzneim.-Forsch./Drug Res. 30 (I):320–324 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Duchateau, G.S.M.J.E., Zuidema, J. & Merkus, F.W.H.M. Bioavailability of Propranolol After Oral, Sublingual, and Intranasal Administration. Pharm Res 3, 108–111 (1986). https://doi.org/10.1023/A:1016345504153
Issue Date:
DOI: https://doi.org/10.1023/A:1016345504153